Bioventus Inc. (Class A) (BVS) exhibits 68.3% gross margins and 10.4% return on invested capital within Health Care (Medical/Dental Instruments), balanced against a 26.3x enterprise multiple and 4.8% implied options volatility.
Sustained 68.3% gross profitability converts into 9.5% operating margin and 10.4% ROIC, outpacing sector cost of capital.
ROIC: 10.4% // GM: 68.3%YoY revenue trajectory of -0.9% paired with 5.77% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -0.9% // FCF YLD: 5.77%Altman Z-Score of 2.25 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 2.25 // F-SCORE: 7/9Trading at 55.0x trailing P/E (51.2x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 55.0x // EV/EBITDA: 26.3xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $13.33 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Medical/Dental Instruments require continuous execution to defend 4.0% net margins.
NET MARGIN: 4.0% // D/E: 1.52x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for BVS & activate live FRED threshold breach alerts.